Australia markets closed

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
16.00+0.43 (+2.76%)
At close: 04:00PM EST
15.20 -0.80 (-5.00%)
After hours: 04:12PM EST

Kura Oncology, Inc.

12730 High Bluff Drive
Suite 400
San Diego, CA 92130
United States
858 500 8800

Full-time employees127

Key executives

NameTitlePayExercisedYear born
Dr. Troy Edward Wilson J.D., Ph.D.Chairman, CEO, Pres & Principal Financial Officer984.61kN/A1969
Ms. Kathleen FordChief Operating Officer689.32k62.51k1947
Dr. Marc Grasso M.D.Advisor651.68kN/A1974
Ms. Kirsten FlowersChief Commercial Officer & Chief Corp. Strategy Officer642.98kN/A1975
Dr. Stephen Dale M.D.Chief Medical Officer811.58kN/A1972
Mr. Thomas DoylePrincipal Accounting Officer & Sr. VP of Fin. and AccountingN/AN/A1971
Mr. Pete De SpainSr. VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. James E. Basta J.D., Esq.Chief Compliance Officer & Corp. Sec.N/AN/A1966
Ms. Teresa Brophy Bair Esq., J.D.Chief Legal Officer & Corp. Sec.N/AN/A1971
Dr. Roger Bakale Ph.D.VP and Head of CMC, Clinical & Commercial ManufacturingN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Corporate governance

Kura Oncology, Inc.’s ISS governance QualityScore as of 28 November 2022 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.